These medications were studied in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome (ODYSSEY OUTCOMES) trials, which showed that the PCSK9 inhibitors, when added to statin therapy for secondary prevention, further reduced the recurrence of ASCVD events [37,38]. Here, PCSK9 is linked to acute coronary syndrome.